Compare CLST & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLST | CELU |
|---|---|---|
| Founded | 1922 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.6M | 50.7M |
| IPO Year | N/A | N/A |
| Metric | CLST | CELU |
|---|---|---|
| Price | $15.05 | $1.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 6.8K | ★ 61.1K |
| Earning Date | 01-22-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | $11,340,000.00 | ★ $40,578,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $76.00 |
| P/E Ratio | $25.67 | ★ N/A |
| Revenue Growth | ★ 133.67 | N/A |
| 52 Week Low | $10.67 | $1.00 |
| 52 Week High | $15.30 | $4.35 |
| Indicator | CLST | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 72.87 | 33.82 |
| Support Level | $15.02 | $1.62 |
| Resistance Level | $15.30 | $2.01 |
| Average True Range (ATR) | 0.04 | 0.13 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 89.33 | 2.82 |
Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It derives income principally from interest earned on loans and investment securities and, to a lesser extent, from fees received in connection with the origination of loans, service charges on deposit accounts, and other services.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.